Coronavirus vaccine: Chinese biotech says jab produced antibodies in more than 90 per cent of people

Some 743 healthy adults were recruited to two randomised control trials – 600 took part in phase II and 143 in phase I. The larger trial showed that the vaccine induced neutralising antibodies in more than 90 per cent of volunteers, who were tested 14 days after receiving two injections, two weeks apart. There were no adverse events reported in the trials. Weidong Yin, chief executive of Sinovac, said: “Our phase I/II study shows CoronaVac is safe and can induce immune response. Concluding our phase I/II clinical studies with these encouraging results is another significant milestone we have achieved in the fight against Covid-19.” He added that the company, which has developed similar inactivated virus vaccines against hepatitis A and B as well as seasonal and pandemic influenza, has already begun to invest in manufacturing facilities.